EUCTR2015-002423-26-FI进行中（未招募）1 期
A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPin study) - STEPin
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 196
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •* Aged 18 to 50 years inclusive
- •* moderate to severe plaque psoriasis with either new onset or lasting for at least 5 years.
- •Additional inclusion criteria may apply , please refer to the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 196
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •* Forms of psoriasis other than plaque-type (e.g., pustular, erythrodermic, guttate, light sensitive, drug induced)
- •* Ongoing use of prohibited treatments
- •* Pregnant or nursing (lactating) women
- •* Women of child-bearing potential not willing to use contraception
- •*Active ongoing inflammatory diseases other than psoriasis or psoriatic arthritis that might confound the evaluation of the benefit of secukinumab therapy
- •Additional exclusion criteria may apply , please refer to the protocol.
研究者
相似试验
进行中（未招募）
1 期
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisEUCTR2015-002423-26-SEovartis Pharma Services AG196
进行中（未招募）
1 期
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-EEovartis Pharma Services AG196
撤回
4 期
A randomized, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52 Weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared to standard treatment with narrow band UVB (STEPin study)plaque psoriasispsoriasis vulgaris10014982NL-OMON43019TFS Trial Form Support BV20
进行中（未招募）
1 期
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000018190Plaque psoriasisEUCTR2015-002423-26-HUovartis Pharma Services AG196
进行中（未招募）
1 期
Study of the efficacy of early intervention with secukinumab 300 mg s.c. compared to narrow-band UVB in patients with new-onset moderate to severe plaque psoriasisPlaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-002423-26-BGovartis Pharma Services AG196